Year |
Citation |
Score |
2009 |
Blankinship MJ, Gregorevic P, Allen JM, Harper SQ, Harper H, Halbert CL, Miller AD, Chamberlain JS. Erratum to "Efficient Transduction of Skeletal Muscle Using Vectors Based on Adeno-associated Virus Serotype 6". Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1482. PMID 28160909 DOI: 10.1038/Mt.2009.135 |
0.699 |
|
2009 |
Gregorevic P, Schultz BR, Allen JM, Halldorson JB, Blankinship MJ, Meznarich NA, Kuhr CS, Doremus C, Finn E, Liggitt D, Chamberlain JS. Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1427-33. PMID 19471246 DOI: 10.1038/Mt.2009.116 |
0.737 |
|
2008 |
Davis J, Westfall MV, Townsend D, Blankinship M, Herron TJ, Guerrero-Serna G, Wang W, Devaney E, Metzger JM. Designing heart performance by gene transfer. Physiological Reviews. 88: 1567-651. PMID 18923190 DOI: 10.1152/Physrev.00039.2007 |
0.54 |
|
2008 |
Gregorevic P, Blankinship MJ, Allen JM, Chamberlain JS. Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 657-64. PMID 18334986 DOI: 10.1038/Mt.2008.28 |
0.704 |
|
2008 |
Gregorevic P, Meznarich NA, Blankinship MJ, Crawford RW, Chamberlain JS. Fluorophore-labeled myosin-specific antibodies simplify muscle-fiber phenotyping. Muscle & Nerve. 37: 104-6. PMID 17691104 DOI: 10.1002/Mus.20877 |
0.638 |
|
2007 |
Townsend D, Blankinship MJ, Allen JM, Gregorevic P, Chamberlain JS, Metzger JM. Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 1086-92. PMID 17440445 DOI: 10.1038/Sj.Mt.6300144 |
0.618 |
|
2007 |
Wang Z, Kuhr CS, Allen JM, Blankinship M, Gregorevic P, Chamberlain JS, Tapscott SJ, Storb R. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 1160-6. PMID 17426713 DOI: 10.1038/Sj.Mt.6300161 |
0.666 |
|
2007 |
Salva MZ, Himeda CL, Tai PW, Nishiuchi E, Gregorevic P, Allen JM, Finn EE, Nguyen QG, Blankinship MJ, Meuse L, Chamberlain JS, Hauschka SD. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 320-9. PMID 17235310 DOI: 10.1038/Sj.Mt.6300027 |
0.786 |
|
2006 |
Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse L, Finn E, Adams ME, Froehner SC, Murry CE, Chamberlain JS. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nature Medicine. 12: 787-9. PMID 16819550 DOI: 10.1038/Nm1439 |
0.744 |
|
2006 |
Blankinship MJ, Gregorevic P, Chamberlain JS. Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 13: 241-9. PMID 16361117 DOI: 10.1016/J.Ymthe.2005.11.001 |
0.701 |
|
2006 |
Salva MZ, Himeda CL, Tai P, Nishiuchi E, Finn EE, Allen JM, Gregorevic P, Blankinship MJ, Meuse LA, Chamberlain JS, Hauschka SD. 561. Novel Tissue-Specific Regulatory Cassettes Direct High-Level Transgene Expression in Skeletal and Cardiac Muscle Molecular Therapy. 13: S216. DOI: 10.1016/J.Ymthe.2006.08.634 |
0.778 |
|
2006 |
Gregorevic P, Blankinship MJ, Minami E, Allen JM, Murry CE, Chamberlain JS. 35. Systemic Administration of rAAV6-Microdystrophin Preserves Muscle Function and Extends Lifespan in the Dystrophin-/Utrophin- Mouse Model of Severe Muscular Dystrophy Molecular Therapy. 13: S15. DOI: 10.1016/J.Ymthe.2006.08.048 |
0.777 |
|
2005 |
Wang Z, Blankinship MJ, Gregorevic P, Little M, Storb RJ, Allen JM, Tapscott SJ, Chamberlain JS, Kuhr CS. 791. Immunity to AAV-Mediated Gene Therapy in a Random-Bred Canine Model of Duchenne Muscular Dystrophy Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.329 |
0.519 |
|
2005 |
Salva MZ, Himeda CL, Tai P, Blankinship MJ, Gregorevic P, Allen JM, Meuse LA, Chamberlain JS, Hauschka SD. 266. Development of rAAV-Based Skeletal and Cardiac Muscle Regulatory Cassettes for Gene Therapy of Duchenne Muscular Dystrophy Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.269 |
0.78 |
|
2004 |
Gregorevic P, Blankinship MJ, Chamberlain JS. Viral vectors for gene transfer to striated muscle. Current Opinion in Molecular Therapeutics. 6: 491-8. PMID 15537050 |
0.756 |
|
2004 |
Blankinship MJ, Gregorevic P, Allen JM, Harper SQ, Harper H, Halbert CL, Miller AD, Miller DA, Chamberlain JS. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 671-8. PMID 15451451 DOI: 10.1016/J.Ymthe.2004.07.016 |
0.779 |
|
2004 |
Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG, Russell DW, Chamberlain JS. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nature Medicine. 10: 828-34. PMID 15273747 DOI: 10.1038/Nm1085 |
0.775 |
|
2004 |
Gregorevic P, Blankinship MJ, Allen JM, Meuse L, Han J, Oakley S, Chamberlain JS. 718. Systemic Gene Transfer to Striated Muscles Using rAAV6 Vectors Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.624 |
0.746 |
|
2004 |
Blankinship MJ, Gregorevic P, Chamberlain JS. 433. Micro-Utrophin as a Therapeutic Protein in rAAV Mediated Gene Therapy for Duchenne Muscular Dystrophy Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.398 |
0.556 |
|
Show low-probability matches. |